These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3220080)

  • 21. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
    Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
    Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
    Liu P; Mao H; Hou P
    Int J Gynecol Cancer; 2006; 16(2):538-48. PubMed ID: 16681723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.
    Pisano C; Vesci L; Foderà R; Ferrara FF; Rossi C; De Cesare M; Zuco V; Pratesi G; Supino R; Zunino F
    Ann Oncol; 2007 Sep; 18(9):1500-5. PubMed ID: 17698835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
    Arvelo F; Poupon MF; Goguel AF; Lizard G; Bourgeois Y; Arriagada R; Le Chevalier T
    J Cancer Res Clin Oncol; 1993; 120(1-2):17-23. PubMed ID: 7903668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
    Berek JS; Schink JC; Knox RM
    Obstet Gynecol; 1989 Oct; 74(4):663-6. PubMed ID: 2797645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of human ovarian cancer cell growth by prostaglandin D2].
    Miyauchi M; Kikuchi Y; Kizawa I; Oomori K; Kita T; Kato K
    Nihon Sanka Fujinka Gakkai Zasshi; 1987 Feb; 39(2):215-20. PubMed ID: 3029247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.
    Liu Y; Chen L; He X; Fan L; Yang G; Chen X; Lin X; DU L; Li Z; Ye H; Mao Y; Zhao X; Wei Y
    Int J Gynecol Cancer; 2008; 18(4):652-9. PubMed ID: 17892458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats.
    Suzuki M; Sekiguchi I; Sato I; Shirasaka T
    Chemotherapy; 1996; 42(6):452-8. PubMed ID: 8957580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of Brucea javanica fruit oil emulsion combined cisplatin on the growth inhibition of transplanted tumor in human ovarian cancer SKOV3 nude mice: an experimental study].
    Zhao Nan ; Li YH; Wu XK; Wang GY; Cai DY; Han FJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):57-62. PubMed ID: 25790676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
    Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.
    Li W; Xu RJ; Lin ZY; Zhuo GC; Zhang HH
    Med Oncol; 2009; 26(2):170-7. PubMed ID: 18988002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of compound Daqiqi decoction combined cisplatin on Bcl-2/Bax expression of nude mice ovarian cancer subcutaneous transplanted tumor].
    Yang YB; Wang S; Li S; Chen R
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1575-9. PubMed ID: 26281601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
    Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
    Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer].
    Xin G; Du J; Zhu L; Yu YH; Li Y; Liu PS
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(47):3367-70. PubMed ID: 22333207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice.
    Alagoz T; Buller RE; Anderson B; Terrell KL; Squatrito RC; Niemann TH; Tatman DJ; Jebson P
    Cancer; 1995 May; 75(9):2313-22. PubMed ID: 7536123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.